CHOICES by Dr. Bosserman™
For Clinicians

The conversation needs more nuance.

“No hormones.” That one-line answer has become a kind of clinical reflex. It treats local vaginal estrogen the same way it treats systemic therapy. It ignores meaningful differences between formulations, timing, symptoms, and long-term health tradeoffs.

Get clinician updates by email See the clinician guides →
The clinical gap

Patients need the patient questions. Clinicians need the doctor science.

The clinical challenge is not only what the evidence says, but how to explain uncertainty, competing risks, symptom burden, and treatment options responsibly — under real clinic constraints.

What CHOICES supports

Better language for a hard conversation.

Educational resources to support — not replace — your clinical judgment and your patients' individualized care.

01

Risk language

Move past “contraindicated” toward route-, dose-, and formulation-specific framing — so risk can be weighed in proportion, not delivered as a closed door.

02

Evidence distinctions

Where the data is strong, where it is mixed, and where it is absent — across vaginal estrogen, systemic therapy, and testosterone in the survivorship setting.

03

Patient-facing tools

Checklists and guides patients can bring to the visit, so the conversation starts organized, specific, and on the same page.

Clinician guides

Prescribing guides you can use now.

Each guide shows its price and where to get it. Educational, not patient-specific advice.

Complete clinician guide · 105 pages

MHT for Women with BRCA1 and BRCA2 Mutations: The Complete CHOICES Clinician Guide

Five clinical scenarios by genotype and age, the estradiol, progesterone and testosterone reference with master citations, a critical appraisal of the key studies, and a testosterone consent conversation. For BRCA1/BRCA2 carriers after risk-reducing surgery, without a breast cancer history.

$40 once in the CHOICES Library, yours to keep. The complete BRCA clinician guide is also included in CHOICES All Access.

Prescribing guide · 15 pages

Testosterone Therapy for Women: Clinician Prescribing Guide

Indications, formulations, monitoring, and where the evidence is still forming.

In Paid, $8 a month or $80 a year. CHOICES All Access includes it too. The testosterone clinician guide is not sold separately.

Prescribing guide · 5 pages

Vaginal Estradiol for GSM: Clinician Prescribing Guide

Local therapy, systemic absorption, and the survivorship evidence base.

Free to everyone.

Short version · 6 pages

MHT for Women with BRCA1/2 Mutations and Risk Reducing BSO: The Clinician Essentials Guide

The two 2026 cohort studies, five scenarios by genotype and age, and shared-decision prompts, in short form.

In Paid, $8 a month or $80 a year. CHOICES All Access includes it too.

Evidence explainer · In Paid Personalization, Not Prohibition The JCO editorial principle behind CHOICES, framed for a clinical audience.
Clinician updates

More clinician guides are coming.

Join the clinician list to hear when new clinician guides and education sessions are released.

Clinician updates

For clinicians and educators. No patient-specific advice is provided by email.

Speaking & education

For grand rounds, workshops, and clinician education inquiries.

Other inquiries — contact CHOICES →
Book Dr. Bosserman →
CHOICES by Dr. Bosserman

Evidence-based hormone, sexual health, and survivorship education for women and clinicians.

CHOICES content is educational and informational only. It is not medical advice, diagnosis, treatment recommendation, or the practice of medicine, and does not establish a physician–patient or healthcare-provider relationship. Do not use it to start, modify, or discontinue any treatment, and do not delay or disregard professional medical advice because of something you read here. Always consult qualified professionals familiar with your medical history; any use of this information is at your own risk. CHOICES content is independent and does not represent City of Hope.

© 2026 CHOICES by Dr. Bosserman™. All rights reserved. Personalization, not prohibition.